Bruce Broussard will leave Humana next year. Jim Rechtin, CEO of the bankrupt En...
A handful of states are moving aggressively to slash drug costs for their reside...
This week, European regulators are considering an appeal from Amylyx Pharmaceuti...
In a major test for biotechnology company eGenesis, gene-edited pig kidneys kept...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Novo Nordisk plans to stop a trial of Ozempic to treat kidney failure after an i...
The Wellcome Trust — the world’s second largest private funder of biomedical res...
Chronic kidney disease was the strongest risk factor for sudden cardiac arrest a...
Some laid-off life sciences workers in Massachusetts have found new positions ea...
Hospitals get tax breaks worth far more than the value of the charity care they ...
Robert F. Kennedy painted himself as a centrist making space for all sides, even...
The next possible Kaiser Permanente strike would take place Nov. 1-8, health car...
Dana-Farber’s split with Mass General Brigham was spurred by a disagreement over...
Sana Biotechnology said Tuesday that it would lay off nearly a third of its empl...
A fraught question for the children of Alzheimer’s: Is it coming for us?
In the latest edition of STAT's Health Tech newsletter: How doctors and nurses s...
